Supernus Pharmaceuticals (NASDAQ:SUPN) is scheduled to announce Q4 earnings results on Tuesday, February 25th, after market close. The consensus EPS Estimate is $0.52 (+2500.0% Y/Y) and the consensus ...

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results tomorrow after ...

NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) will likely be releasing its earnings data after the market closes ...

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by equities research analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a research report issued ...

After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...

Fintel reports that on February 19, 2025, Cantor Fitzgerald downgraded their outlook for Supernus Pharmaceuticals ...

The phase IIb study results of Supernus Pharmaceuticals Inc.’s SPN-820 in treatment-resistant depression had pulled the company’s stock (NASDAQ:SUPN) down 15.6% on Feb. 19. The randomized, ...

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...

Supernus Pharmaceuticals (NASDAQ:SUPN) stock drops as depression candidate SPN-820 misses main goals in Phase 2b trial. Read more here.

Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...